1. Home
  2. LNZA vs IVA Comparison

LNZA vs IVA Comparison

Compare LNZA & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LNZA
  • IVA
  • Stock Information
  • Founded
  • LNZA 2005
  • IVA 2011
  • Country
  • LNZA United States
  • IVA France
  • Employees
  • LNZA N/A
  • IVA N/A
  • Industry
  • LNZA Major Chemicals
  • IVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • LNZA Industrials
  • IVA Health Care
  • Exchange
  • LNZA Nasdaq
  • IVA Nasdaq
  • Market Cap
  • LNZA 199.8M
  • IVA 162.8M
  • IPO Year
  • LNZA N/A
  • IVA 2020
  • Fundamental
  • Price
  • LNZA $0.20
  • IVA $3.22
  • Analyst Decision
  • LNZA Hold
  • IVA Strong Buy
  • Analyst Count
  • LNZA 2
  • IVA 4
  • Target Price
  • LNZA $2.00
  • IVA $13.25
  • AVG Volume (30 Days)
  • LNZA 4.4M
  • IVA 8.7K
  • Earning Date
  • LNZA 05-08-2025
  • IVA 03-26-2025
  • Dividend Yield
  • LNZA N/A
  • IVA N/A
  • EPS Growth
  • LNZA N/A
  • IVA N/A
  • EPS
  • LNZA N/A
  • IVA N/A
  • Revenue
  • LNZA $58,025,000.00
  • IVA $15,243,814.00
  • Revenue This Year
  • LNZA N/A
  • IVA $18.05
  • Revenue Next Year
  • LNZA $77.26
  • IVA $46.74
  • P/E Ratio
  • LNZA N/A
  • IVA N/A
  • Revenue Growth
  • LNZA 7.99
  • IVA N/A
  • 52 Week Low
  • LNZA $0.20
  • IVA $1.53
  • 52 Week High
  • LNZA $3.41
  • IVA $3.98
  • Technical
  • Relative Strength Index (RSI)
  • LNZA 26.07
  • IVA 50.87
  • Support Level
  • LNZA $0.22
  • IVA $2.88
  • Resistance Level
  • LNZA $0.33
  • IVA $3.10
  • Average True Range (ATR)
  • LNZA 0.06
  • IVA 0.22
  • MACD
  • LNZA -0.00
  • IVA -0.01
  • Stochastic Oscillator
  • LNZA 10.76
  • IVA 30.37

About LNZA LanzaTech Global Inc.

LanzaTech Global Inc is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The company's goal is to reduce the need for virgin fossil fuels by challenging and striving to change the way the world uses carbon.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: